About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science

Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery.

Autifony is using its pioneering approach to develop novel treatments for serious disorders of the central nervous system, such as Schizophrenia, Fragile X, Alzheimer’s Disease and potentially other diseases which represent major unmet medical needs.

The company is also one of the leaders in pharmaceutical approaches to the treatment of hearing disorders. Hearing disorders affect a significant proportion of the population, and while devices such as hearing aids and cochlear implants can ease the problems for some, many people suffer silently. As well as causing social isolation and distress, hearing loss also brings with it a considerable economic cost to society, with increased risk of unemployment, the need for carer support, and other costs.

By targeting specific ion channels which regulate neuronal activity, our new drugs will help to alleviate symptoms of Schizophrenia, Fragile X, Alzheimer’s Disease and reduce symptoms associated with hearing loss.

Management Team & Board of Directors


Investors

Autifony Therapeutics Limited is a privately funded company. The main investors are:

Additional Funding

Additional Funding for Autifony has also been obtained from UCL Business and from The International Biotechnology Trust (IBT).

Related News

30May

Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

0 Comments
Stevenage, UK – 30 May 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
15Apr

Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator

0 Comments
• AUT00206 reduces the ketamine-induced BOLD response in a randomized placebo-controlled Phase Ib trial • Results are highly supportive of... Read More →
18Jan

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

0 Comments
Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
18Dec

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

0 Comments
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image